GE Healthcare China announced on April 10 that its new positron emission tomography system, SIGNA PET/MR, was officially launched. The breakthrough innovation of this PET/MR is: PET detector with TOF technology is realized by the latest generation SiPM full digital solid-state array photoelectric converter, with high-end 3.0T mute magnetic resonance as the platform, ZTE* technology is used to achieve precision. PET attenuation correction enables true PET and MR integrated simultaneous scanning. More importantly, SIGNA PET/MR is based on precision quantitative technology, which opens up a new era of precision quantitative imaging, and is the first to promote future-oriented molecular targeted imaging clinical applications, delivering accurate image care.

In recent years, the incidence of major diseases such as malignant tumors, nervous system diseases, cardiovascular and cerebrovascular diseases has increased year by year in China, and the current medical resources investment is still concentrated in the later diagnosis, treatment, screening and early detection work is still gradually explored. In the process, the challenge of serious illness is becoming more and more serious. In the face of challenges, GE Healthcare continues to invest in medical imaging technology innovation and expand its research and development in precision medicine. With breakthrough image quality and rich image information, it will improve the accuracy of diagnosis and medical efficiency, and promote the early detection and diagnosis of major diseases.

Ms. Zheng Ping, Chief Operating Officer of GE Healthcare Greater China, said: “With the heart of care, GE Healthcare continues to innovate in imaging technology. As another proof of GE Healthcare’s strategy of 'care first”, SIGNA PET/MR is accurate. Quantitative applications break through the bottleneck of imaging technology, improve medical care with cutting-edge technology, and lead the future trend of accurate images."

Integrated scanning to achieve "new leap" of accurate images

SIGNA PET/MR integrates industry-leading TOF and ZTE technologies* to achieve a new leap in precision imaging, guided therapy and therapeutic evaluation.

Integrated Synchronous Scanning: Integrated PET/MR integrates TOF-PET detectors with MR body coils. The new SiPM detector realizes TOF function, enabling PET with complete and advanced magnetic resonance imaging capabilities. All the features to achieve true PET and MR simultaneous scanning.

Accurate quantification: PET/MR uses the latest 3.0T mute magnetic resonance equipment as a platform to achieve precise PET attenuation correction with revolutionary ZTE technology to help accurate quantitative diagnosis.

Fast scanning speed, low dose, high image quality: LBS镥 scintillation crystal and SiPM solid-state array photoelectric converter combine to bring super PET detector, which realizes TOF technology on integrated PET/MR for the first time, with time resolution Increased to below 400ps*, sensitivity up to 21cps/kBq*, effectively eliminates “positive electron penetration” artifacts and “hot organ” artifacts, reduces false positives and false negatives, greatly improves scanning speed while dramatically increasing image Resolution, reduced tracer injection dose, for a more accurate and safe scanning experience, expand its application in nervous system, brain function research, tumor, cardiovascular, pediatric and physical examination screening.

Breaking through tradition and creating a new benchmark for accurate images

Accurate quantitative imaging and molecular imaging are the focus and trend of imaging technology development, and will provide more abundant and effective support for clinical diagnosis, guiding treatment and efficacy evaluation. The innovative SIGNA PET/MR breaks through the challenges of traditional medical imaging technology, based on the quantitative precision of PET-specific tracer, promotes the clinical application of molecular targeted imaging, and creates a “new benchmark” for accurate imaging based on individualized treatment. The truly integrated scanning of the innovative integrated PET/MR enables effective detection of small lesions, early accurate diagnosis, personalized treatment and efficacy evaluation in the fields of nervous system, tumor, cardiovascular, pediatric and physical examination screening.

Nervous system diseases: PET/MR can provide more accurate quantitative diagnostic information for early accurate diagnosis of neurological related Parkinson's disease, dementia and epilepsy;

Tumor: PET/MR provides higher diagnostic efficacy in the diagnosis of brain, head and neck, abdominal cavity, and pelvic organ tumors. Among them, MR adopts multi-parameter and multi-contrast imaging technology, and on the basis of ensuring high soft tissue resolution, smaller soft tissue lesions can be found.

Cardiovascular: PET/MR offers unique value in the field of coronary plaque imaging, myocardial viability testing and cardiac function assessment. PET/MR breakthrough synchronous scanning can simultaneously provide high-resolution anatomical structure of myocardial MR and PET perfusion, metabolic images, which can greatly enhance the doctor's clinical diagnostic confidence.

Pediatric and physical examination screening: lymphoma, skeletal tumor and soft tissue tumor in children's tumors are high incidence of disease, SIGNA PET / MR has low dose and rapid whole body scanning advantages, early diagnosis and accurate for children's tumors Staging and efficacy evaluation provide important value.

API Products

An active substance is the main active ingredient in a drug. Take a simple aspirin for example. Acetyl salicylic acid is synthesized through chemical process and purified to a specified purity. The synthesis of acetyl salicylic acid is made by adding various excipients, such as fillers, adhesives, disintegrating agents, etc., and then pressing it into tablets. The production of apis is generally either pure chemical synthesis, biological fermentation, or semi-synthesis, with biological fermentation followed by extraction followed by synthesis. Not all pharmaceutical enterprises make API by themselves, and many manufacturers do not have the scale to produce API. Even if there is large-scale production, the cost of production may be much higher than that of procurement. Therefore, most manufacturers buy bulk drugs, and then make preparations, so that the production of drugs can be completed without a very large scale. At present, China and India have become the two largest API producers in the world. Many European and American pharmaceutical companies, even some of their own original drugs, will give up the production of API as the patent expires and the market matures, and turn to purchase apis from China and India,API production generally go through laboratory, generated through laboratory bottle container canister, taking after successful, pilot magnification, which is to enlarge the quantity of the production, then no problem tends to be faced with a lot of small scale experiment, a very simple example, the heating process, due to the relatively small amount in the laboratory, uneven heating cases is less, But if it is scaled up to a few tons of pot, at this time the heating may be not hot in this place, where the paste pot, at this time you need to stir, but the speed of mixing is appropriate, this process needs to calculate or grope. Finally from the pilot test, and then to the formal production, the volume of further amplification, and will face a lot of new problems. Therefore, although some drugs are generic, the research and development of the whole process from small test, pilot test to the final mass production is indispensable, so even generic drugs have very high research and development costs.

api meaning,api products to buy,best api products,cheap api products,best buy products api,best api products

Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropic.com